Related Experiment Videos
Thromboembolic complications associated with brain tumors
1Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, Houston, USA.
Journal of Neuro-Oncology
|January 1, 1994
Summary
Thromboembolic complications in cancer patients stem from hemostasis alterations. Brain tumors specifically contribute to these risks through tumor-related factors and defective fibrinolysis.
Area of Science:
- Oncology
- Hematology
- Neurosurgery
Background:
- Thromboembolic complications are a leading cause of death in hospitalized cancer patients.
- The fibrinolytic system is crucial for dissolving blood clots and is implicated in both normal and malignant cell behavior.
- Defective fibrinolysis, an imbalance in clot dissolution, is linked to venous thrombosis and other thromboembolic events.
Purpose of the Study:
- To discuss factors associated with thromboembolic complications in patients with brain tumors.
- To explore the role of hemostatic alterations and defective fibrinolysis in brain tumor-associated thrombosis.
Main Methods:
- Review of literature on thromboembolic complications in cancer patients, with a focus on brain tumors.
- Analysis of hemostatic alterations, including tumor-induced changes and interactions with neural tissue.
- Examination of defective fibrinolysis in relation to specific brain tumor types and locations.
Main Results:
- Cancer patients exhibit hemostatic alterations leading to thromboembolic events.
- Brain tumors can directly or indirectly cause hemostatic changes.
- Defective fibrinolysis is associated with specific brain tumor characteristics and locations, increasing thromboembolic risk.
Conclusions:
- Thromboembolic complications in brain tumor patients are multifactorial.
- Understanding these factors is crucial for managing and preventing thrombotic events in neuro-oncology patients.